Reference
FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors Internet Document : 28 Sep 2022. Available from: URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sodium-thiosulfate-reduce-risk-ototoxicity-associated-cisplatin-pediatric-patients
Rights and permissions
About this article
Cite this article
FDA approves Pedmark for preventing cisplatin-induced hearing loss. Reactions Weekly 1926, 3 (2022). https://doi.org/10.1007/s40278-022-24281-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-24281-y